Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)
Featured Articles
(FDA.gov) Apr 10, 2019 - During the morning session, the committee will discuss new drug application (NDA) 211810 for pexidartinib capsule, submitted by Daiichi Sankyo, Inc. The proposed indication (use) for this product is for the treatment of adult patients with symptomatic tenosynovial giant cell tumor also referred to as giant...
Read Article
(Celgene) Apr 5, 2019 - Celgene Corporation and Acceleron Pharma Inc. today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia who have ring...
Read Article
Latest Articles
April 18, 2019
April 18, 2019
April 17, 2019
April 16, 2019
April 16, 2019
April 15, 2019
April 10, 2019
April 10, 2019
View More
News Commentary
Editor Image
09 Jul, 2018 | by Winston Wong, PharmD
The math is simple. Under the proposed agreement, we pay for all doses of the...
View Comment
View More
OBR Blog
As the ASH Annual Meeting concludes, the late-breaking abstracts are always of great interest. We take a brief look at... Read more
December 04, 2018
As the 2018 American Society of Hematology (ASH) Annual Meeting continues, we focus on two studies that have the... Read more
December 04, 2018